Do analysts rate LEXX or HEPA?

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LEXX or HEPA more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Hepion Pharmaceuticals N/A -812.56% -207.31%

Does the media prefer LEXX or HEPA?

In the previous week, Lexaria Bioscience had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Lexaria Bioscience and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.36 beat Lexaria Bioscience's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hepion Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NCNA or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, NCNA or HEPA?

NuCana is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is NCNA or HEPA more profitable?

NuCana's return on equity of -41.90% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts recommend PCSA or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PCSA or HEPA?

Heatwurx is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is PCSA or HEPA more profitable?

Heatwurx's return on equity of -394.25% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Hepion Pharmaceuticals N/A -812.56% -207.31%

Does the media refer more to PCSA or HEPA?

In the previous week, Heatwurx had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Heatwurx and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.36 beat Heatwurx's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hepion Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HEPA or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, HEPA or GLMD?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is HEPA or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Galmed Pharmaceuticals N/A -73.68% -60.88%

Does the media favor HEPA or GLMD?

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Hepion Pharmaceuticals' score of 0.36 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hepion Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HEPA or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HEPA or INM more profitable?

InMed Pharmaceuticals' return on equity of -156.08% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% InMed Pharmaceuticals N/A -156.08% -123.90%

Does the media favor HEPA or INM?

In the previous week, InMed Pharmaceuticals had 11 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 12 mentions for InMed Pharmaceuticals and 1 mentions for Hepion Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.79 beat Hepion Pharmaceuticals' score of 0.36 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hepion Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hepion Pharmaceuticals (HEPA) Competitors

$0.12 -0.01 (-4.00%)

As of 10/9/2026 02:27 PM Eastern

Compare

HEPA vs. LEXX, NCNA, PCSA, GLMD, and INM

Should you buy Hepion Pharmaceuticals stock or one of its competitors? Hepion Pharmaceuticals's main competitors and comparable companies include Lexaria Bioscience (LEXX), NuCana (NCNA), Heatwurx (PCSA), Galmed Pharmaceuticals (GLMD), and InMed Pharmaceuticals (INM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Hepion Pharmaceuticals compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

In the previous week, Lexaria Bioscience had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Lexaria Bioscience and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.36 beat Lexaria Bioscience's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hepion Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lexaria Bioscience has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lexaria Bioscience's return on equity of -174.93% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Lexaria Bioscience has higher revenue and earnings than Hepion Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Summary

Lexaria Bioscience beats Hepion Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to NuCana?

NuCana (NASDAQ:NCNA) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, NuCana and NuCana both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.36 beat NuCana's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NuCana	Neutral
Hepion Pharmaceuticals	Neutral

NuCana is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

NuCana has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

44.0% of NuCana shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NuCana's return on equity of -41.90% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NuCana beats Hepion Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Heatwurx is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Heatwurx's return on equity of -394.25% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Heatwurx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Heatwurx had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Heatwurx and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.36 beat Heatwurx's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heatwurx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hepion Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Heatwurx beats Hepion Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -73.68% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Hepion Pharmaceuticals' score of 0.36 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hepion Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

Summary

Galmed Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to InMed Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, InMed Pharmaceuticals had 11 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 12 mentions for InMed Pharmaceuticals and 1 mentions for Hepion Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.79 beat Hepion Pharmaceuticals' score of 0.36 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hepion Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMed Pharmaceuticals' return on equity of -156.08% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

InMed Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
InMed Pharmaceuticals	$4.94M	0.91	-$12.56M	-$1.64	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

InMed Pharmaceuticals beats Hepion Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37M	$12.29B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.03	797.58	275.30	26.16
Price / Sales	N/A	939.75	635.97	107.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.09	10.71	11.22	6.33
Net Income	-$48.93M	$2.84B	$3.50B	$382.15M
7 Day Performance	N/A	-0.94%	-0.89%	-1.40%
1 Month Performance	N/A	-4.89%	-4.42%	-3.47%
1 Year Performance	N/A	-4.12%	7.03%	1.18%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.12 -4.0%	N/A	+51.9%	$1.37M	N/A	N/A	20	Upcoming Earnings Gap Down
LEXX Lexaria Bioscience	1.8125 of 5 stars	$3.15 +0.6%	$22.50 +614.3%	-75.2%	$5.17M	$710K	N/A	7	News Coverage Analyst Upgrade Gap Up
NCNA NuCana	1.3489 of 5 stars	$1.35 +11.6%	N/A	-81.5%	$5.04M	N/A	N/A	11	Positive News Gap Up High Trading Volume
PCSA Heatwurx	1.1639 of 5 stars	$1.64 -6.8%	N/A	-84.5%	$4.87M	N/A	N/A	12	Positive News Short Interest Decrease Gap Up High Trading Volume
GLMD Galmed Pharmaceuticals	0.7411 of 5 stars	$4.59 -0.9%	N/A	-63.1%	$4.78M	N/A	N/A	20	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. LEXX, NCNA, PCSA, GLMD, and INM

How does Hepion Pharmaceuticals compare to Lexaria Bioscience?

Summary

How does Hepion Pharmaceuticals compare to NuCana?

Summary

How does Hepion Pharmaceuticals compare to Heatwurx?

Summary

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. LEXX, NCNA, PCSA, GLMD, and INM

How does Hepion Pharmaceuticals compare to Lexaria Bioscience?

Does the media prefer LEXX or HEPA?

Do analysts rate LEXX or HEPA?

Which has more risk & volatility, LEXX or HEPA?

Do institutionals and insiders believe in LEXX or HEPA?

Is LEXX or HEPA more profitable?

Which has better valuation and earnings, LEXX or HEPA?

Summary

How does Hepion Pharmaceuticals compare to NuCana?

Does the media prefer NCNA or HEPA?

Which has higher valuation and earnings, NCNA or HEPA?

Which has more risk & volatility, NCNA or HEPA?

Do insiders and institutionals believe in NCNA or HEPA?

Is NCNA or HEPA more profitable?

Do analysts recommend NCNA or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Heatwurx?

Do analysts recommend PCSA or HEPA?

Which has higher earnings and valuation, PCSA or HEPA?

Is PCSA or HEPA more profitable?

Which has more volatility and risk, PCSA or HEPA?

Do insiders & institutionals have more ownership in PCSA or HEPA?

Does the media refer more to PCSA or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Do analysts prefer HEPA or GLMD?

Do insiders and institutionals believe in HEPA or GLMD?

Is HEPA or GLMD more profitable?

Does the media favor HEPA or GLMD?

Which has more volatility and risk, HEPA or GLMD?

Which has preferable valuation & earnings, HEPA or GLMD?

Summary

How does Hepion Pharmaceuticals compare to InMed Pharmaceuticals?

Does the media favor HEPA or INM?

Is HEPA or INM more profitable?

Which has preferable earnings & valuation, HEPA or INM?

Do analysts recommend HEPA or INM?

Which has more risk and volatility, HEPA or INM?

Do institutionals & insiders hold more shares of HEPA or INM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools